Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 15/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 10/20 | 0.41 |
| ▸ | CTSB | P07858 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 5/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSC | P53634 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712691 | 0.76 | — | — | |
| SCHEMBL21069200 | 0.76 | — | — | |
| SCHEMBL799561 | 0.75 | AKT1 (0.39) | USP30AKT1 | |
| SCHEMBL799022 | 0.75 | AKT1 (0.39) | USP30AKT1 | |
| SCHEMBL799377 | 0.75 | AKT1 (0.39) | USP30AKT1 | |
| SCHEMBL18123328 | 0.73 | AKT1 (0.38) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL21556664 | 0.73 | AKT1 (0.38) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL13382849 | 0.73 | AKT1 (0.41) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL13382854 | 0.73 | AKT1 (0.41) | USP30UCHL1CTSBCTSKCTSS | |
| SCHEMBL18925005 | 0.73 | AKT1 (0.38) | USP30UCHL1CTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073277-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073273-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | disclosed |